This study highlights that inhibition of PDE4B can effectively decrease alcohol intake and preference while providing therapeutic benefits for AD; this is associated with the upregulation of cAMP and its downstream phosphorylation of PKA/CREB. Here, PDE4B is linked to Alzheimer disease.